Trevena, Inc. Completes Phase 2a Study of TRV027 in Patients With Advanced Heart Failure
10/8/2012 9:53:11 AM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction. TRV027 was generally well-tolerated in this study and produced beneficial hemodynamic effects in line with those observed in previously published pre-clinical studies. Trevena is developing TRV027 for the intravenous hospital treatment of acute decompensated heart failure (ADHF), and these data support the advancement of TRV027 into a future study to evaluate its clinical efficacy in patients with ADHF.